#TKI🧠
LightNews LightNews
alkpositiveuk.bsky.social
🚨 Big #ALK+ #lungcancer trial update! Nuvalent says pivotal ALKOVE-1 results expected this year—bringing neladalkib (NVL-655) closer to approval.

This next-gen ALK inhibitor tackles resistance mutations & 🧠 mets. A Phase 3 trial for TKI-naïve ALK+ NSCLC is also starting. 🔗 shorturl.at/3f9EX #LCSM
January 14, 2025 at 11:30 AM
handle.invalid
🧬 JYP0322: a highly selective, brain-penetrant ROS1 TKI shines at #AACR25!
⚡ 79% ORR in TKI-naive
⚡ 57% ORR in pretreated patients
🧠 Early signs of CNS activity
🛡️ No DLTs, MTD not reached
Hope rising for ROS1+ #NSCLC patients facing resistance! #LCSM @theaacr.bsky.social
April 28, 2025 at 4:51 PM
onco404.bsky.social
📍 TKI-Naïve vs. TKI-Pretreated Patients
✅ 88.8% vs. 55.8% confirmed ORR
🧠 Strong CNS Efficacy: 76.5% vs. 65.6% intracranial (IC)-cORR
✅ Median DoR: 44.2 vs. 16.6 months
✅ Median PFS: 45.6 vs. 9.7 months

📍 Robust activity against G2032R mutations (61.5% ORR)

#Onco404 #NSCLC #MedSky #OncSky
April 5, 2025 at 2:55 PM
onclive.bsky.social
🚀 The FDA has granted Priority Review to neladalkib (NVL-655) for patients with TKI-pretreated ALK+ NSCLC, backed by ALKOVE-1 data showing durable systemic and intracranial activity in heavily pretreated disease. 🧠📊
Read more ➡️ www.onclive.com/view/fda-gra...
#LungCancer #NSCLC #ALK #Oncology
FDA Grants Priority Review to Neladalkib for TKI-Pretreated ALK+ NSCLC | OncLive
The FDA priority review of neladalkib for TKI-pretreated ALK-positive NSCLC is supported by data from the phase 1/2 ALKOVE-1 trial.
www.onclive.com
May 27, 2026 at 4:53 PM
handle.invalid
🚨 #AACR25: JYP0322, inhibidor ROS1 de 3ª gen en CPNM (NSCLC) ROS1+
🔬 TRO (ORR) 85.7% en mutación G2032R resistente
🧠 TRO intracraneal (IC-ORR) 42.9%, TCE (DCR) 73.5%
🛡️ Sin TLD (DLT), DMT (MTD) no alcanzada
🧬 Alta penetración al SNC
💡 Firme candidato a cambiar el manejo post-TKI
#LCSM #Oncologia
April 29, 2025 at 4:20 PM
vjoncology.bsky.social
At #ESMO25, Emmanuel Seront discusses the RENALUT trial of ¹⁷⁷Lu-PSMA-617 in metastatic ccRCC

💥 PSMA-targeted radioligand therapy after TKI + ICI progression
🎯 Evaluating response, PFS, OS, & safety
🧠 Imaging-guided treatment w/ added cycles for responders

🎥 buff.ly/sswLUyk

#kcms #UroOnc #UroSoME
RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology
Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...
buff.ly
October 20, 2025 at 2:54 PM
onclive.bsky.social
📣 The FDA has accepted an sNDA for taletrectinib in advanced ROS1-positive NSCLC, supported by updated TRUST-I/II data showing ~90% ORR, durable responses, and strong CNS activity 🧠📊
⏳ PDUFA date set for January 2027
Read more ➡️ www.onclive.com/view/fda-acc...
#LungCancer #NSCLC #ROS1 #Oncology
FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC | OncLive
An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC
www.onclive.com
May 6, 2026 at 5:58 PM
kaisaunkila.bsky.social
Missiona #aivoterveys ja #TKI🧠. Haemme Kansalliseen Neurokeskukseen koordinaattoria (Kuopio). Haku 23.5 mennessä. Hakukuulutus täällä: www.uef.fi/fi/avoimet-t...

@uniuef.bsky.social @tkubrainmindcenter.bsky.social @hkibrainmind.bsky.social @uniofjyvaskyla.bsky.social @trebrainmind.bsky.social
Avoimet työpaikat
Itä-Suomen yliopiston avoimet työpaikat, professorien tehtävien tehtäväselosteet sekä muiden tehtävien ja dosentin arvon hakemiseen liittyvät ohjeet.
www.uef.fi
May 8, 2025 at 2:21 AM